Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination

Beatty, Alexis L.; Peyser, Noah D.; Butcher, Xochitl; Cocohoba, Jennifer; Lin, Feng; Olgin, Jeffrey E.; Pletcher, Mark J.; Marcus, Gregory M.

doi:10.1001/jamanetworkopen.2021.40364

Cited by 314 publications

(333 citation statements)

References 21 publications

(76 reference statements)

Supporting

Mentioning

276

Contrasting

Unclassified

Order By: Relevance

“…Besides, women were less likely to report side effects following vaccination than their male counterparts. This is a mixed finding, with most studies reporting higher side effects among males [25][26][27][28][29] and others reporting the opposite [27]. Moreover, older people (>50 years) were more likely to report vaccine side effects than the younger ones, which also disagrees with most other studies [19,25,28].…”

Section: Discussionmentioning

confidence: 86%

Side Effects of COVID-19 Vaccines and Perceptions about COVID-19 and Its Vaccines in Bangladesh

Maqbool

Mahmud

Mian³

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: One of the primary reasons for hesitancy in taking COVID-19 vaccines is the fear of side effects. This study primarily aims to inspect the potential side effects of the COVID-19 vaccines circulated in Bangladesh. Methods: The study was a cross-sectional anonymous online survey conducted across Bangladesh. Data were collected from December 2 to December 26, 2021. The study included consenting (informed) Bangladeshi individuals aged 12 and above who had received at least one dose of the COVID-19 vaccines. Analyses were carried out through exploratory analysis, Chi-square test, and logistic regression. Results: A total of 1,180 ( males-63.89%, age 50 years or over-65.4%, rural-52.86%) vaccinated people participated in the study. Less than half of the participants (39.48%) reported at least one side effect after receiving their COVID-19 vaccine. Injection-site pain, fever, headache, redness/swelling at the injection site, and lethargy were the most commonly reported adverse effects, all of which were mild and lasted 1-3 days. Side effects were most prevalent (about 80%) among individuals who received Pfizer-BioNTech and Moderna vaccines and were least common among those who received Sinopharm and Sinovac vaccines (21%-28%). When compared to the Sinopharm vaccines, the OxfordAstraZeneca, Pfizer-BioNTech, and Moderna vaccines were 4.51 (95% CI: 2.53-8.04) times, 5.37 (95% CI: 2.57-11.22) times, and 4.28 (95% CI: 2.28-8.05) times likelier to produce side effects. Furthermore, males, those over 50 years old, urban dwellers, smokers, and those with underlying health issues had a considerably increased risk of developing side effects. A lack of confidence in vaccines' efficacy and a substantial level of hesitancy in allowing children (age five years or over) and older people (70 years or over) to receive COVID-19 vaccines were also observed. Conclusion: Side effects of COVID-19 vaccines are minimal, demonstrating their safety. Further studies are required to establish the efficacy of the vaccines.

show abstract

Section: Discussionmentioning

confidence: 86%

Side Effects of COVID-19 Vaccines and Perceptions about COVID-19 and Its Vaccines in Bangladesh

Maqbool

Mahmud

Mian³

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…On the other hand, Beatty A.L. et al [15] showed that the mRNA-1273 vaccine increased ORs 1.88 times (95% CI, 1.63-2.17) the odds of severe or very severe AEs (p < 0.001) compared to BNT162b2 vaccine.…”

Section: Discussionmentioning

confidence: 99%

The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data

Lee

Shim

et al. 2022

Vaccines

View full text Add to dashboard Cite

Two mRNA COVID-19 vaccines (mRNA-1273, Moderna; and BNT162b2, Pfizer-BioNTech) and one viral vector vaccine (JNJ-78436735, Janssen/Johnson and Johnson) are authorized in the US to hinder COVID-19 infections. We analyzed severe and common adverse events in response to COVID-19 vaccines using real-world, Vaccine Adverse Effect Reporting System (VAERS) data. From 14 December 2020 to 30 September 2021, 481,172 (50.7 ± 17.5 years, males 27.89%, 12.35 per 100,000 people) individuals reported adverse events (AEs). The median time to severe AEs was 2 days after injection. The risk of severe AEs following the one viral vector vaccine (OR = 1.044, 95% CI = 1.005–1.086) was significantly higher than that after the two mRNA vaccines, and the risk among males (OR = 1.374, 95% CI = 1.342–1.406) was higher than among females, except for anaphylaxis. For common AEs, however, the risk to males (OR = 0.621, 95% CI = 0.612–0.63) was lower than to females. In conclusion, we provided medical insight and clinical guidance about vaccine types by characterizing AEs using real-world data. In particular, COVID-19 mRNA vaccines are safer than viral vector vaccines with regard to coagulation disorders, whereas inflammation-related AEs are lower in the viral vaccine. The risk–benefit ratio of vaccines should be carefully considered, and close monitoring and management of severe AEs is needed.

show abstract

“…Table 1 outlines the advantages and disadvantages of various vaccine platforms that have been utilized for the development of COVID-19 vaccines. Reports have indicated that the currently available vaccines are associated with minor side effects, including headache, nausea, and pain/soreness at the injection site, although rare and unusual adverse events have also been observed for specific types of COVID-19 vaccines [7].…”

Section: Multiple Vaccine Platformsmentioning

confidence: 99%

Coronavirus disease 2019 (COVID-19) vaccine platforms: how novel platforms can prepare us for future pandemics: a narrative review

Lee¹,

Shin²

2022

J Yeungnam Med Sci

View full text Add to dashboard Cite

According to the World Health Organization (WHO), as of December 2021, there have been more than 260 million confirmed coronavirus disease 2019 (COVID-19) cases, of which over 5 million have resulted in death, and over 7.9 billion doses of vaccines administered worldwide [1]. The Americas remain the region with the greatest number of confirmed COVID-19 cases, accounting for approximately 40% of all reported cases. In the Republic of Korea, over 4,077 of the 496,584 confirmed cases of COVID-19 have resulted in death, and over 42 million vaccine doses have been administered. Due to the rapid global spread of More than 2 years after the explosion of the coronavirus disease 2019 (COVID-19) pandemic, extensive efforts have been made to develop safe and efficacious vaccines against infections with severe acute respiratory syndrome coronavirus 2. The pandemic has opened a new era of vaccine development based on next-generation platforms, including messenger RNA (mRNA)-based technologies, and paved the way for the future of mRNA-based therapeutics to provide protection against a wide range of infectious diseases. Multiple vaccines have been developed at an unprecedented pace to protect against COVID-19 worldwide. However, important knowledge gaps remain to be addressed, especially in terms of how vaccines induce immunogenicity and efficacy in those who are elderly. Here, we discuss the various vaccine platforms that have been utilized to combat COVID-19 and emphasize how these platforms can be a powerful tool to react quickly to future pandemics.

show abstract

Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination

Cited by 314 publications

References 21 publications

Side Effects of COVID-19 Vaccines and Perceptions about COVID-19 and Its Vaccines in Bangladesh

Side Effects of COVID-19 Vaccines and Perceptions about COVID-19 and Its Vaccines in Bangladesh

The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data

Coronavirus disease 2019 (COVID-19) vaccine platforms: how novel platforms can prepare us for future pandemics: a narrative review

Contact Info

Product

Resources

About